Our mission statement
The III. Medical University Hospital sees itself as a university-level medical institution that wants to realize the claim of all patients for the best possible and most modern diagnostic and therapeutic care.
This claim applies to patients with all diseases listed in the care mandate of the III. Medicine, i. e. patients with all kinds of tumor diseases, benign and malignant changes in the blood-forming system, coagulation disorders, HIV infection and rheumatological diseases.
Primar Univ.-Prof. Dr. Richard Greil
Admission of station: 16.103
Outpatient frequency: 45.115
Nursing days: 44.035
Available beds: 115
Ø Occupancy rate in %: 101,1
The quantitatively overwhelming aspect of the care assignment in basic and clinical research as well as in in the optimal care of patients at the cutting edge of science lies in the field of internal oncology and hematology.
For the catchment area of the federal state of Salzburg and beyond, the III. Medical Clinic is on the one hand the primary start-up, clarification and therapeutic care facility for patients with tumor diseases, on the other hand It has also the task of serving as a secondary and tertiary reference facility in the national and international environment. Patients are offered the opportunity to obtain a second opinion and access to the latest treatment modalities and new substances within the framework of the earliest clinical studies of III. to find medicine that is often not available in other places.
The III. Medical Clinic and its employees place maximum value on a patient – oriented form of care, which guarantees maximum speed, efficiency and quality in consultation, clarification and care in all phases of the illnesses. The aim is to combine the highest scientific quality with the best possible human attention to the existential, human, family and social problems of patients through the necessary sequence of investigations in a targeted and protected manner while at the same time providing the multidisciplinary network of cooperation with other disciplines around which the III. Medicine traditionally cares for and which is the prerequisite for the success of the best possible care.
Cooperation, coordination and interdisciplinary therapies
This networking of the care of our patients with other SALK facilities and beyond is achieved on the one hand by numerous regular and close interdisciplinary meetings with other SALK clinics involved in the treatment of tumour patients. In this respect, the III. Medicine together with the Salzburg State Government and the SALK to further expand the Center for Interdisciplinary Tumor Therapy at the SALK, as decided by the Salzburg State Government in the SGS in 2006. In order to provide all patients in the province of Salzburg with optimal oncological care regardless of their place of residence, III. Medicine also cultivated a close cooperation with other hospitals in the federal state of Salzburg. In particular, regular cooperation is maintained with the hospitals in Zell am See, Mitternsill, Tamsweg, Hallein and Oberndorf as well as the hospitals in Zell am See, Schwarzach und Mittersill also a direct consultation and consultation is carried out on site. This coordination function is carried out on behalf of the Salzburg State Government and corresponds to the function of a reference center for hematology and internal oncology in accordance with the ÖSG 2006.
Our research for the development of targeted therapy strategies
In order to be able to perceive and realize the performance requirements of a top medical university care, a close and self-evident combination of basic scientific and translational research, state-of-the-art and future-oriented application-oriented diagnosis of molecular and immunological prediction factors required for course of disease and response to treatment with clinical study and research activities on the one hand. In the basic approach of the III. Medicine it provides the basic necessary understanding of targeted modern therapy strategies by working on the molecular and immunological causes of tumor diseases. This part of the research activity is carried out by the Laboratory for Immunological and Molecular Cancer Research of III. Medicine (LIMCR), which is the closest collaboration with all clinically active employees of the III. Medicine is marked, This ensures an optimal integration of research into the concerns of patients and thus the development of future solutions for tumor diseases. With 24 research staff, this laboratory is the largest basic science research laboratory at the PMU Salzburg, The insights gained from this interaction between patient care and state-of-the-.art research are translated into state-of-the-art methods for diagnosing tumor and leukemia diseases and new definitions of risk factors. In the medium term, this is intended to enable individualized therapy that is optimally tailored to the individual patient. This is done by close networking with the Molecular Cytological Diagnostic Laboratory of the III. Medicine.
Centre for Clinical Trials
Oncology is developing extremely rapidly, especially due to the long-standing efforts to understand the complex cell biological and molecular foundations of tumor formation. The III. Medicine sees itself as an institution that wants to provide all patients with the optimal and sensible treatment option.
In doing so, we strive to work for our patients at the forefront of oncological clinical research in order to be able to offer our patients medications and forms of care, even in very difficult situations, which can otherwise only be used in the drug market for approval and thus for use in a few years. It was for this reason that the III. Medicine established a Center for Clinical Cancer and Immunology Trials, which provides the professional prerequisite for offering state-of-the-art studies with new substances in the fields of tumor diseases, hematology, HIV and rheumatology. At present, the work of the physicians of the III. Medicine established and funded clinical trial center conducted more than 150 clinical trials. This maximum embedding in the international clinical research landscape is the basic prerequisite for a modern form of university medical care. The III. Medicine has historically worked closely with the Department of Special Gynaecology and other SALK facilities and has been working closely with these clinics in the Salzburg Breast Centre for decades. The III. Medicine also plays the coordinating role of the clinical trials of the ABSCG (Austrian Breast and Colon Cancer Study Group) for a substancial part of western Austria and is responsible for the inauguration and implementation quality of these studies for this globally renowned clinical study group for research into new treatment options for breast cancer and colon cancer (www.abcsg.at).
The development of patient numbers – a sign of confidence
The III. Medicine developed massively compared to the year 2003. The number of inpatients and day-clinical patients undergoing system treatment has almost doubled, ant the proportion of patients treated with lymph node cancer or leukaemia or requiring high-close therapy with stem cell transplantation has tripled to quadrupled.
Patients’ confidence in all forms of tumor diseases of solid organs has been reflected in a correspondingly massive increase in the number of patients receiving support and treatment through the III. Medicine. We are aware of the responsibility and trust of patients in this care and will continue to intensively try to live up to this responsibility.
The above-mentioned increase in the quality of services offered at the III. Medicine also necessitated a plethora of interim modifications to the building structure and equipment, as waiting for the final construction of the new building would not have done justice to the massive speed of the content-related and quantitative performance development. The necessary changes are only due to the patient’s high level of patience and expectation, the extreme willingness of the nursing staff of the III. Medicine. This was made possible by the support of the Salzburg State Government and the Supervisory Board of SALK. This is reflected in the expansion and conversion of the III. Medicine. I would like to thank all of you and ask for your continued patience and support. This is all the more so as the corresponding development and implementation of top-level medicine combined with a doubling of the number of patients entails considerable costs. The struggle to make these funds available to our patients is of essential importance for the medical and research location of Salzburg, but also for the quality of life and the social embedding of sick people in the middle of society and ultimately for social peace. We would like to express our gratitude for the understanding and support of politicians, the media and the public, as well as for the support of our colleagues.